Bill Text: HI SR88 | 2022 | Regular Session | Amended
Bill Title: Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.
Spectrum: Partisan Bill (Democrat 10-0)
Status: (Passed) 2022-06-06 - Certified copies of resolutions sent, 06/06/22. [SR88 Detail]
Download: Hawaii-2022-SR88-Amended.html
|
THE SENATE |
S.R. NO. |
88 |
|
THIRTY-FIRST LEGISLATURE, 2022 |
S.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
SENATE RESOLUTION
REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A THERAPEUTIC PSILOCYBIN WORKING GROUP TO EXAMINE THE MEDICINAL AND THERAPEUTIC EFFECTS OF PSILOCYBIN AND DEVELOP A LONG‑TERM STRATEGIC PLAN, should food and Drug Administration approval for medical use be obtained, TO enable the availability of therapeutic psilocybin or psilocybin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older.
WHEREAS, mental health conditions are treated in various ways depending on the condition and can include medication, therapy, and psychosocial services; and
WHEREAS, these treatments, while effective for certain conditions and patients, do not treat all mental health conditions; and
WHEREAS, psilocybin is a naturally-occurring chemical compound found in certain species of mushrooms; and
WHEREAS, psilocybin can activate serotonin receptors in the brain; and
WHEREAS, studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress; and
WHEREAS, the United States Food and Drug Administration has determined that preliminary clinical evidence indicates that psilocybin may demonstrate substantial improvement over available therapies for treatment-resistant depression and has granted a breakthrough therapy designation for a treatment that uses psilocybin as a therapy for treatment-resistant depression; and
WHEREAS, Hawaii has a shortage of mental health professionals, and should actively consider novel, innovative, and safe solutions to treat its citizens; now, therefore,
BE IT RESOLVED by the Senate of the Thirty-first Legislature of the State of Hawaii, Regular Session of 2022, that the Department of Health is requested to convene a Therapeutic Psilocybin Working Group, to be placed within the Department of Health for administrative purposes; and
BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to examine:
(1) Federal, state, and local laws, regulations, administrative rules, and procedures regarding the therapeutic use of psilocybin;
(2) Available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin in treating mental health conditions; and
(3) The requirements, specifications, and guidelines for a medical professional to prescribe and provide psilocybin to patients in jurisdictions where psilocybin is approved to treat mental health conditions; and
BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to develop a long-term strategic plan, should Food and Drug Administration approval for medical use be obtained, to enable the availability of therapeutic psilocybin or psilocybin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older; and
BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Therapeutic Psilocybin Working Group:
(1) The Director of Health, who is requested to serve as chairperson of the working group;
(2) The Attorney General;
(3) The Dean of the John A. Burns School of Medicine at the University of Hawaii at Manoa;
(4) The chairpersons of the Senate and House of Representatives standing committees whose subject matter purview is primarily responsible for reviewing legislation relating to health and the Judiciary;
(5) The chairperson of the Hawaii State Council on Mental Health;
(6) A physician duly licensed under chapter 453, Hawaii Revised Statutes, or advanced practice registered nurse with the authority to prescribe psychotropic medication and duly licensed under chapter 457, Hawaii Revised Statutes, to be invited by the chairperson of the working group; and
(7) A psychiatrist duly licensed under chapter 453, Hawaii Revised Statutes, to be invited by the chairperson of the working group; and
BE IT FURTHER RESOLVED that the chairperson of the Therapeutic Psilocybin Working Group may invite other interested parties with relevant experience to join the working group; and
BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group is requested to submit:
(1) A preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2023; and
(2) A final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024; and
BE IT FURTHER RESOLVED that the Therapeutic Psilocybin Working Group be dissolved on July 1, 2024; and
BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the Director of Health, Attorney General, and Dean of the John A. Burns School of Medicine.
Therapeutic Psilocybin Working Group; Department of Health
